B+
Bull case
30%
Probability
Target price
$82.00
+20.2% vs current
PTCT
PTC TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$72.00
+5.5% vs current
B-
Bear case
25%
Probability
Target price
$54.00
-20.9% vs current
AI sentiment snapshot
Latest data as of 2026-05-09
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+52.2
Score
AI commentary
Near-term sentiment improved after the 2026-05-07 earnings release: AP framed both EPS and revenue as ahead of Zacks-tracked expectations, and PTCT traded about 14% above the 2026-05-07 anchor by 2026-05-09. Even so, this remains a medium-conviction post-earnings follow-up because confirmed analyst target/rating revisions were not clearly available in checked sources and social coverage was not part of the packet.
RankAlpha Sentiment Codex - 2026-05-09
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-07catalystQ1 beat and 2026 revenue guidance raise reset near-term expectationsHigh impact
PTC reported Q1 2026 revenue of $272.6M, including $225.6M of product revenue, and raised 2026 product revenue guidance to $750M-$850M with total revenue guidance of $1.08B-$1.18B; Sephience revenue reached $124.6M with 36% quarter-over-quarter growth, supporting a stronger near-term commercial setup [#8-K-2026-05-07]. Associated Press said results beat Zacks-tracked consensus on both EPS and revenue.
2026-08-07eventVatiquinone registration study start is the next visible FA regulatory recovery checkpointHigh impact
Management said, after April 2026 FDA feedback, it expects to initiate an open-label registration study for vatiquinone in Q3 2026 using a matched natural-history control to support NDA resubmission. That gives investors a dated next step after the prior CRL, but it remains an execution and evidentiary risk [#8-K-2026-05-07] [#10-Q-2026-05-07].
2027-05-09catalystVotoplam/Novartis development progress can extend pipeline optionality and cash supportHigh impact
PTC disclosed positive 24-month PIVOT-HD extension data for votoplam, said Novartis and PTC will review potential regulatory interactions, and the 10-Q disclosed that Novartis initiated the first Phase III trial on April 23, 2026, triggering a $50M milestone payable to PTC in Q2 2026. This supports longer-duration pipeline value and non-dilutive cash inflow, though timing of regulatory translation remains uncertain [#8-K-2026-05-07] [#10-Q-2026-05-07].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-09 • Updated nightlySource: Internal modelMethodology